Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer

Published: Wednesday, July 11, 2012
Last Updated: Wednesday, July 11, 2012
Bookmark and Share
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.

QIAGEN N.V. has announced that it has received U.S. Food and Drug Administration (FDA) approval to market the therascreen® KRAS RGQ PCR Kit (therascreen KRAS test) to provide guidance on the use of Erbitux® (cetuximab) as a treatment in patients with metastatic colorectal cancer.

The U.S. FDA approval of the KRAS test kit marks a milestone in QIAGEN's global expansion of its Personalized Healthcare franchise which includes an industry-leading portfolio of molecular companion diagnostics to aid treatment decisions in oncology.

QIAGEN already markets a broad range of companion diagnostic tests covering 30 biomarkers in Europe, Asia/Pacific and Japan.

"We are very pleased to receive FDA approval to launch our therascreen KRAS test in the United States and to play a role in transforming the care of colorectal cancer patients. This approval marks an important step for QIAGEN, but also an important step in Personalized Healthcare, as we are now launching a major molecular companion diagnostic product in the U.S.," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.

Schatz continued, "With a growing portfolio of innovative tests and efficient automation platforms, we are proud to be helping to make healthcare more effective, providing ways for payers to more efficiently use healthcare resources and, most important, making a positive impact on the care of patients."

Pioneering role in Personalized Healthcare

QIAGEN is at the forefront of developing and validating a range of tests that provide physicians with an individual patient's molecular information to select the most appropriate medicines.

The entry into the U.S. market with the approval of the first therascreen test builds on our success in the European market, where QIAGEN offers 10 CE-marked assays, based either on real-time PCR technology or on Pyrosequencing.

QIAGEN currently markets therascreen assays in Europe for biomarkers including KRAS, EGFR, NRAS, BRAF, PI3K, JAK2, MGMT and UGT1A1.

In Japan, the therascreen KRAS and EGFR kits were approved in 2011, solidifying QIAGEN's leadership position for companion diagnostics in the second biggest market for Personalized Healthcare.

A range of assays and related Sample & Assay Technologies are also marketed to customers use during the research and development of new medicines.

QIAGEN is actively expanding its pipeline of Personalized Healthcare technologies and intends to submit several companion diagnostics in the coming years for U.S. regulatory approval.

QIAGEN has more than 15 projects under way to co-develop and market companion diagnostics with leading pharmaceutical and biotech companies such as Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, and Pfizer.

Benefiting patients and providers

Introduction of the therascreen KRAS test provides an FDA-approved diagnostic available for making treatment decisions for colorectal cancer patients.

Approximately 110,000 colorectal cancer patients each year in the U.S. could benefit from KRAS testing, according to QIAGEN estimates.

Studies show the U.S. healthcare system could save more than $600 million annually by avoiding unnecessary use of medicines in colorectal cancer patients through determinations of their KRAS status.

In metastatic colorectal cancer patients for whom standalone surgery and chemotherapy are insufficient, treatment with an epidermal growth factor receptor (EGFR) inhibitor has been shown to improve overall survival. However, the presence or absence of KRAS mutations in tumors affects outcomes: Approximately 60% of patients with mutation-negative (wild-type) KRAS genes may benefit from anti-EGFR therapy, while 40% whose tumors have KRAS mutations may not benefit.

The first FDA approval of the therascreen KRAS test pairs this companion diagnostic with Erbitux®, a leading EGFR inhibitor marketed in the U.S. by Bristol-Myers Squibb in partnership with Eli Lilly and its ImClone Systems unit.

According to the U.S. product information for Erbitux®, KRAS status evaluation using an FDA-approved diagnostic test is used to determine treatment, and the therascreen KRAS kit is currently the only test with this status.

Based on the FDA approval for use in metastatic colorectal cancer patients, the current annual U.S. market potential for sales of the therascreen KRAS kit in this indication only is approximately $20 million.

In contrast to laboratory-developed tests (LDTs), the FDA-approved therascreen KRAS test gives healthcare providers a fast, consistent and reliable process to determine optimal treatment for colorectal cancer patients who are candidates for EGFR-inhibitor therapy.

The therascreen KRAS kit has been shown to have higher sensitivity (i.e. a lower limit of detection, LOD) for KRAS mutations between 0.8% and 6.4% depending on the assay which is critical to ensuring reliable and consistent data for treatment decisions.

Following FDA approval, a number of laboratories will begin offering KRAS status evaluation with the therascreen KRAS test:

• Applied Diagnostics, Inc.
• Boyce & Bynum Pathology Laboratories
• Cellnetix Pathology & Laboratories
• Clinical Molecular Oncology Laboratory, The University of Kansas Medical Center
• Colorado Molecular Correlates Laboratory (CMOCO), University of Colorado
• Companion Dx Reference Lab, LLC
• Dahl-Chase Diagnostic Services
• Lab21 Inc.
• Mayo Clinic


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics
Master collaboration agreement is a framework for developing and commercializing QIAGEN companion diagnostics, paired with new or existing products.
Thursday, November 13, 2014
QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Receives FDA Approval for CMV Assay
Assay offers faster quantification of CMV DNA levels in patient samples.
Friday, June 20, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
FDA Approve QIAGEN PCR Kit For Use With Second Colorectal Cancer Drug
Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen’s Vectibix® (panitumumab) in treatment of metastatic colorectal cancer.
Tuesday, May 27, 2014
QIAGEN Receives FDA Clearance for QIAsymphony RGQ MDx
Clearance marks a milestone for one of the Company’s major global growth drivers.
Monday, May 05, 2014
QIAGEN Licences Biomarker for Blood Disorder from CeMM Vienna
Company plans to develop a molecular diagnostic test for the calreticulin mutations.
Thursday, April 10, 2014
QIAGEN Partners with Exosome Diagnostics
Molecular testing of biofluids promises unprecedented access to gene mutations, gene expression signatures and expression levels without costly, invasive tissue biopsies.
Wednesday, July 24, 2013
QIAGEN Acquires Ingenuity Systems
Suite of web-based applications powered by a unique expert-curated Knowledge Base eases major bottlenecks to leveraging genomic data in research and clinical diagnostics.
Thursday, May 02, 2013
QIAGEN’s KRAS Companion Diagnostic for Colorectal Cancer Adopted by Clarient
Clarient offers network of 2,000-plus pathologists testing with therascreen KRAS RGQ PCR Kit, the companion diagnostic for Erbitux® in metastatic colorectal cancer.
Wednesday, January 30, 2013
QIAGEN Submits Companion Diagnostic to FDA
Companion diagnostic intended to aid treatment decisions in non-small cell lung cancer.
Tuesday, January 22, 2013
QIAGEN Adds to Pipeline of Personalized Healthcare Diagnostics
Includes investment in new companion diagnostic that aims to predict efficacy of TNF-alpha inhibitors in rheumatoid arthritis patients.
Tuesday, January 08, 2013
QIAGEN Unveils Initiative to Create Next-generation Sequencing Portfolio
Company plans to offer sample-to-result workflows that integrate its sample preparation and assay products with a next-generation benchtop sequencer and new bioinformatics.
Tuesday, June 26, 2012
QIAGEN Receives FDA Clearances for Rotor-Gene Q MDx Instrument and Compatible Influenza A/B Assay
Both products receive 510(k) clearance for in vitro diagnostic use in the U.S..
Tuesday, April 17, 2012
Qiagen Subsidiary SABiosciences Expands RT2 Profiler PCR Arrays
Now more than 100 arrays for various disease areas available
Monday, July 05, 2010
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Simple Technology Makes CRISPR Gene Editing Cheaper
University of California, Berkeley, researchers have discovered a much cheaper and easier way to target a hot new gene editing tool, CRISPR-Cas9, to cut or label DNA.
HPV Genomes Show Greater Diversity Than Expected in Cancer Patients
The findings could have implications for eventually understanding why some cervical lesions become malignant.
Rapidly Detecting Drug-Resistant HepC
A nested PCR-based assay has been shown to rapidly and accurately detect drug-resistant strains of the hepatitis C virus.
Researchers Seek Water Test for Invasive Species Detection
Detecting invasive lake and river species using just a water sample would be a dream come true for wildlife managers and regulators in the state and University of Maine researchers may soon make this an inexpensive reality.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Ebola Assays Compared in Head-to-Head Analysis
A newly published study has attempted to rigorously evaluate a few of the assays recently granted Emergency Use Authorization by the US Food and Drug Administration to test for Ebola Zaire virus.
Profiling DNA Viruses in Arctic Lakes
The Arctic's freshwater lakes contain viral communities composed of DNA viruses from lineages that are largely distinct from those described elsewhere, a new study suggests.
Polar Distribution of MicroRNAs Discovered within Eukaryotic Cells
A plausible new mechanism contributing to asymmetric cell division.
A New Role for Zebrafish: Larger Scale Gene Function Studies
A relatively new method of targeting specific DNA sequences in zebrafish could dramatically accelerate the discovery of gene function and the identification of disease genes in humans.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!